Pyxis Oncology Inc’s recent filing unveils that its CFO & COO Connealy Pamela Ann acquired Company’s shares for reported $0.17 million on Nov 26 ’24. In the deal valued at $1.96 per share,88,850 shares were bought. As a result of this transaction, Connealy Pamela Ann now holds 1,199,143 shares worth roughly $1.09 million.
William Blair downgraded its Pyxis Oncology Inc [PYXS] rating to a Mkt perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Stifel began covering PYXS with “Buy” recommendation on August 08, 2024.
Price Performance Review of PYXS
On Friday, Pyxis Oncology Inc [NASDAQ:PYXS] saw its stock fall -2.57% to $0.91. Over the last five days, the stock has lost -14.01%. Pyxis Oncology Inc shares have fallen nearly -41.57% since the year began. Nevertheless, the stocks have fallen -83.64% over the past one year. While a 52-week high of $5.88 was reached on 01/07/25, a 52-week low of $0.91 was recorded on 04/04/25. SMA at 50 days reached $1.2328, while 200 days put it at $2.5927.
Levels Of Support And Resistance For PYXS Stock
The 24-hour chart illustrates a support level at 0.8673, which if violated will result in even more drops to 0.8230. On the upside, there is a resistance level at 0.9488. A further resistance level may holdings at 0.9860. The Relative Strength Index (RSI) on the 14-day chart is 36.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0995, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.66%. Stochastics %K at 17.97% indicates the stock is a buying.
How much short interest is there in Pyxis Oncology Inc?
A steep rise in short interest was recorded in Pyxis Oncology Inc stocks on 2025-03-14, growing by 47785.0 shares to a total of 6.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 6.88 million shares. There was a rise of 0.69%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 09, 2024 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
